Autoantibodies in Immune Checkpoint Inhibitor-Related Endocrinopathies
Immune checkpoint inhibitors (ICIs) have been established as a standard treatment for many types of cancer; however, they present a clinical challenge due to unique side effects known as immune-related adverse events (irAEs). Endocrine irAEs include the more frequently reported thyroid and pituitary dysfunctions, as well as less frequent, but potentially severe conditions, such as ICI-related type 1 diabetes and primary adrenal insufficiency. These can lead to life-threatening complications, thus requiring careful management. Their pathogenesis is thought to be an autoimmune response. Recent reports have identified various autoantibodies in patients with endocrine irAEs, drawing attention to their clinical significance. This review describes the clinical features and presumed pathogenic mechanisms of endocrine irAEs. Furthermore, it comprehensively summarizes the autoantibodies reported for each endocrine irAE and discusses their significance based on the latest findings, focusing on their utility as predictive biomarkers for irAE onset, their diagnostic value, and their potential involvement in the pathogenesis.
Authors
- Shintaro Iwama (ORCID: https://orcid.org/0000-0002-3281-0337)
- Hiroshi Arima (ORCID: https://orcid.org/0000-0003-3746-1997)
- Tomoko Kobayashi
Institutions
- Nagoya University Hospital (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2026-11-19
- DOI
- https://doi.org/10.2169/internalmedicine.8222-26
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00